T. Thuren
Epidemiology · 2011–2017
A researcher in the Science corpus: 4 papers; trusts 1 researcher and is trusted by 1 researcher here, as inferred from the citation graph.
Subfields
- Epidemiology — 27 citations into it; #1,922 of 2,148 by trust here, #461 by citations
- Surgery — 19 citations into it
Whom T. Thuren trusts overall
Their strongest outbound trust, strongest first, inferred from their citations.
Who trusts T. Thuren overall
Papers from T. Thuren's perspective
Ordered by how strongly the researchers T. Thuren trusts endorse each paper. Same corpus, a different order for every researcher.
- The IL-1 family: regulators of immunity (Nature reviews. Immunology)
- C-reactive protein and the prediction of cardiovascular events among those at intermediate risk: moving an inflammatory hypothesis toward consensus. (Journal of the American College of Cardiology)
- Interleukin-1-receptor antagonist in type 2 diabetes mellitus. (New England Journal of Medicine)
- Mutation of a new gene encoding a putative pyrin-like protein causes familial cold autoinflammatory syndrome and Muckle–Wells syndrome (Nature Genetics)
- Type 2 diabetes as an inflammatory disease (Nature reviews. Immunology)
- Use of canakinumab in the cryopyrin-associated periodic syndrome. (New England Journal of Medicine)
- Inflammation in Atherosclerosis: From Pathophysiology to Practice (Journal of the American College of Cardiology)
- Immunological and inflammatory functions of the interleukin-1 family. (Annual Review of Immunology)
- C-reactive protein levels and outcomes after statin therapy. (New England Journal of Medicine)
- The immune response in atherosclerosis: a double-edged sword (Nature reviews. Immunology)
Their papers
- Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease (2017) — 7,832 citations
- Effect of interleukin-1β inhibition with canakinumab on incident lung cancer in patients with atherosclerosis: exploratory results from a randomised, double-blind, placebo-controlled trial. (2017) — 983 citations
- Interleukin-1β inhibition and the prevention of recurrent cardiovascular events: rationale and design of the Canakinumab Anti-inflammatory Thrombosis Outcomes Study (CANTOS). (2011) — 833 citations
- Relationship of C-reactive protein reduction to cardiovascular event reduction following treatment with canakinumab: a secondary analysis from the CANTOS randomised controlled trial. (2017) — 783 citations